pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Alunbrig
drug
save

brigatinib

Marketedupdated 4mo ago
by Takeda Pharmaceuticals USA Inc
Approved
community read0 votes

indications

investigational
NSCLC

all catalysts(0)

nothing on the calendar yet

Trials studying brigatinib

  • —Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancerrecruitingn=500
  • phase2Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotypingactive not recruitingn=118
  • —A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)active not recruitingn=154
  • phase2Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)active not recruitingn=100
  • phase2Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumorsrecruitingn=65
  • phase3A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancercompletedn=248
  • phase2A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinibcompletedn=103
  • —A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.completedn=5,279
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
May 22, 2027
267 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

  • Nov 10, 2035compositionUS 10385078
  • Nov 10, 2035compositionUS 10385078
  • Nov 10, 2035compositionUS 10385078
  • Apr 10, 2034method-of-use (U-2837)US 9611283
  • Apr 10, 2034method-of-use (U-2837)US 9611283
  • Apr 10, 2034method-of-use (U-2837)US 9611283
  • Apr 28, 2031compositionUS 90124624.7y
  • Apr 28, 2031compositionUS 90124624.7y
  • Apr 28, 2031compositionUS 90124624.7y
  • May 21, 2029method-of-use (U-2837)US 92730772.7y
  • May 21, 2029method-of-use (U-2837)US 92730772.7y
  • May 21, 2029method-of-use (U-2837)US 92730772.7y

FDA exclusivities (3)

  • May 22, 2027ODE-300Orphan Drug (7y)267d
  • May 22, 2027ODE-300Orphan Drug (7y)267d
  • May 22, 2027ODE-300Orphan Drug (7y)267d

News(0)

no news has mentioned this drug yet

brand
Alunbrig
generic
brigatinib
indication
Non-Small Cell Lung Cancer
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?